Alentis Therapeutics Appoints Lung Experts Professors Tony M

BASEL, Switzerland--(BUSINESS WIRE)--#CLDN1--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong a...

Related Keywords

Hong Kong , France , University Of Hong Kong , Hong Kong General , Johannesburg , Gauteng , South Africa , Switzerland , Long Island Jewish Medical Center , New York , United States , Sariette Witte , Steven Nathan , Tony Mok , Los Angeles , Luigi Manenti , Thomas Baumert , Opatrick Wilson , Sinai Medical Center , University Of Virginia , Department Of Clinical Oncology , Drug Administration , Stephen College Council , Therapy Devices Panel , Program At Inova Fairfax Hospital , Lung Transplant Program At Inova Fairfax Hospital , French National Institute Of Health Inserm , Chinese University Of Hong Kong , University Of Strasbourg , Claudin Technology Platform , Alenti Claudin Technology Platform , Astrazeneca , University Of The Witwatersrand , Li Shu Fan Medical Foundation , Hong Kong Academy Of Sciences , Alentis Therapeutics , Clinical Oncology , Chinese University , Scientific Advisory , Scientific Advisory Board , Chief Medical Officer , Medical Director , Advanced Lung Disease , Transplant Program , Inova Fairfax Hospital , Aurora Tele Oncology , College Council , Hong Kong Academy , New England Journal , Clarivate Analytics , Lung Transplant Program , Cedars Sinai Medical Center , Respiratory Therapy Devices , French National Institute ,